RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
36 hedge funds and large institutions have $27.8M invested in RVL Pharmaceuticals plc Ordinary Shares in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 5 closing their positions.
1,750% more call options, than puts
Call options by funds: $111K | Put options by funds: $6K
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
49% more capital invested
Capital invested by funds: $18.7M → $27.8M (+$9.13M)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
16% more funds holding
Funds holding: 31 → 36 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$891K |
| 2 |
MWM
Marietta Wealth Management
Marietta,
Georgia
|
+$172K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$156K |
| 4 |
BlackRock
New York
|
+$77.7K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$46.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.22M |
| 2 |
Renaissance Technologies
New York
|
-$528K |
| 3 |
Two Sigma Investments
New York
|
-$233K |
| 4 |
Morgan Stanley
New York
|
-$132K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$76K |
RVLP Hedge Fund Activity: Q1 2022 in Review
36 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q1 2022, worth a combined $27.8M — up 49% from $18.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new RVLP positions and 5 closed out — a net gain of 5 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $891K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.22M sold.
- 36 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q1 2022, up from 31 in Q4 2021.
- Funds reported $27.8M of RVL Pharmaceuticals plc Ordinary Shares stock for Q1 2022, up 49% quarter-over-quarter.
- 10 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q1 2022 and 5 closed out, a net change of +5 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q1 2022 was ArrowMark Colorado Holdings, an estimated $891K added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q1 2022 was Alyeska Investment Group, an estimated $1.22M sold.
Based on aggregated 13F filings for Q1 2022.